vx-770 and Fatty-Liver

vx-770 has been researched along with Fatty-Liver* in 1 studies

Other Studies

1 other study(ies) available for vx-770 and Fatty-Liver

Article	Year
Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy. Journal of pediatric gastroenterology and nutrition, 2015, Volume: 60, Issue:5 Treatment of liver disease, including hepatic steatosis, in patients with cystic fibrosis (CF) is limited. With the development of ivacaftor, which corrects the gating defect of the CF transmembrane regulator channel, there is a potential new therapy available for this subgroup of the CF patient population. We present an adolescent with CF who had significant improvement in hepatic steatosis with ivacaftor treatment while hypothesizing on a mechanism of why it occurred. Topics: Adolescent; Aminophenols; Cystic Fibrosis; Fatty Liver; Female; Humans; Quinolones; Radiography	2015

Article

Year

Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.

Journal of pediatric gastroenterology and nutrition, 2015, Volume: 60, Issue:5

Treatment of liver disease, including hepatic steatosis, in patients with cystic fibrosis (CF) is limited. With the development of ivacaftor, which corrects the gating defect of the CF transmembrane regulator channel, there is a potential new therapy available for this subgroup of the CF patient population. We present an adolescent with CF who had significant improvement in hepatic steatosis with ivacaftor treatment while hypothesizing on a mechanism of why it occurred.

Topics: Adolescent; Aminophenols; Cystic Fibrosis; Fatty Liver; Female; Humans; Quinolones; Radiography

2015